Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.62 -1.5%	$2.00	$1.05 ▼ $4.13	$355.06M	1.96	616,396 shs	829,699 shs
CMPX Compass Therapeutics	$2.41	$2.00	$0.77 ▼ $4.08	$333.26M	1.41	954,588 shs	746,462 shs
SLDB Solid Biosciences	$4.51 -1.5%	$3.26	$2.41 ▼ $10.37	$349.59M	2.22	1.15 million shs	1.23 million shs
XBIT XBiotech	$2.64 -4.3%	$2.94	$2.57 ▼ $8.32	$80.49M	0.97	73,866 shs	73,201 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-1.77%	+112.65%	+95.93%	+14.40%
CMPX Compass Therapeutics	0.00%	-3.60%	+19.31%	-2.03%	+100.83%
SLDB Solid Biosciences	0.00%	-0.66%	+74.13%	-11.39%	-43.13%
XBIT XBiotech	0.00%	-8.97%	-11.41%	-20.24%	-57.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	2.5872 of 5 stars	3.5	3.0	3.2	0.8	0.6
CMPX Compass Therapeutics	3.5636 of 5 stars	4.6	1.0	2.7	5.0	0.0
SLDB Solid Biosciences	3.8633 of 5 stars	4.6	3.0	2.9	1.7	1.3
XBIT XBiotech	1.0809 of 5 stars	0.0	2.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$8.50	135.13% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	444.61% Upside
SLDB Solid Biosciences	3.23	Buy	$14.90	230.38% Upside
XBIT XBiotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIT, SLDB, CMPX, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/13/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$75.82M	4.73	N/A	N/A	($1.93) per share	-1.87
CMPX Compass Therapeutics	$850K	392.07	N/A	N/A	$1.17 per share	2.06
SLDB Solid Biosciences	$8.09M	43.21	N/A	N/A	$6.27 per share	0.72
XBIT XBiotech	$4.01M	20.07	N/A	N/A	$7.19 per share	0.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$240.05M	-$1.45	N/A	N/A	N/A	-300.00%	N/A	-61.33%	8/5/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	8/12/2025 (Estimated)
XBIT XBiotech	-$24.56M	-$1.29	N/A	∞	N/A	N/A	-15.99%	-14.85%	8/11/2025 (Estimated)

Latest XBIT, SLDB, CMPX, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/14/2025	Q1 2025	XBIT XBiotech	N/A	-$0.36	N/A	-$0.36	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million
3/18/2025	Q4 2024	XBIT XBiotech	N/A	-$0.34	N/A	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.92	4.68
CMPX Compass Therapeutics	N/A	31.84	31.84
SLDB Solid Biosciences	N/A	7.85	7.85
XBIT XBiotech	N/A	11.57	11.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CMPX Compass Therapeutics	68.43%
SLDB Solid Biosciences	81.46%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
CMPX Compass Therapeutics	29.80%
SLDB Solid Biosciences	1.90%
XBIT XBiotech	33.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	92.73 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
SLDB Solid Biosciences	100	77.52 million	35.05 million	Optionable
XBIT XBiotech	100	30.49 million	20.39 million	Optionable

XBIT, SLDB, CMPX, and ADCT Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average - Here's Why

June 14 at 3:54 AM | marketbeat.com

XBiotech (NASDAQ:XBIT) Share Price Crosses Below 50-Day Moving Average - What's Next?

May 25, 2025 | marketbeat.com

XBiotech (NASDAQ:XBIT) Stock Crosses Below 50 Day Moving Average - What's Next?

May 17, 2025 | marketbeat.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.com

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.com

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.com

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.com

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.com

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.com

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 16, 2025 | accessnewswire.com

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 15, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 14, 2025 | accessnewswire.com

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 13, 2025 | accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 12, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, SLDB, CMPX, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.62 -0.06 (-1.50%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$3.61 -0.01 (-0.14%)

As of 06/13/2025 07:47 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Compass Therapeutics NASDAQ:CMPX

$2.41 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.00 (+0.21%)

As of 06/13/2025 07:23 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Solid Biosciences NASDAQ:SLDB

$4.51 -0.07 (-1.53%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.48 -0.03 (-0.67%)

As of 06/13/2025 07:23 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

XBiotech NASDAQ:XBIT

$2.64 -0.12 (-4.35%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.64 -0.01 (-0.19%)

As of 06/13/2025 04:04 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time